Genitourinary Cancers | Specialty

Cabozantinib, Nivolumab Active in Metastatic Urothelial Carcinoma

September 20th 2017

Cabozantinib and nivolumab with or without ipilimumab show activity in genitourinary tumors, particularly urothelial carcinoma, and have manageable safety profiles.

FDA Panel Splits on Adjuvant Sunitinib in High-Risk RCC

September 20th 2017

The FDA’s Oncologic Drugs Advisory Committee voted 6-6 on the potential approval of sunitinib for use as an adjuvant therapy in patients with renal cell carcinoma who have received nephrectomy and are at high risk of recurrence.

Dr. Lalani on Neutrophil-Lymphocyte Ratio in RCC

September 19th 2017

Aly-Khan Lalani, MD, genitourinary oncology fellow, Dana-Farber Cancer Institute, discusses neutrophil-lymphocyte ratio in renal cell carcinoma.

Dr. McGregor Discusses the Future of Treatment for RCC

September 19th 2017

Bradley McGregor, MD, physician, Genitourinary Oncology program, Dana-Farber Cancer Institute, instructor of medicine, Harvard Medical School, discusses the future of treatment for renal cell carcinoma.

FDA Approves Reduced Dose of Cabazitaxel for mCRPC

September 18th 2017

The FDA has approved a cabazitaxel (Jevtana) regimen of 20 mg/m2 every 3 weeks in combination with prednisone for the treatment of men with metastatic castration-resistant prostate cancer.

Enzalutamide Succeeds in Phase III Nonmetastatic CRPC Trial

September 14th 2017

Adding enzalutamide to androgen deprivation therapy (ADT) significantly improved metastasis-free survival versus ADT alone in patients with nonmetastatic castration-resistant prostate cancer, according to findings from the phase III PROSPER trial.

Dr. Pal Compares CheckMate-214 and CABOSUN Trials in RCC

September 13th 2017

Sumanta K. Pal, MD, medical oncologist, assistant clinical professor, Department of Medical Oncology and Therapeutics Research, City of Hope, discusses both the CheckMate-214 and CABOSUN trials for patients with renal cell carcinoma (RCC).

PFR Unaffected by Sequence of Cytoreductive Nephrectomy and Sunitinib in Patients With Synchronous mRCC

September 12th 2017

Treating primary tumors by administering targeted therapy with sunitinib (Sutent) prior to cytoreductive nephrectomy did not improve the progression-free rate at 28 weeks over a sequence of immediate CN followed by sunitinib in patients with synchronous metastatic renal cell carcinoma.

Nivolumab/Ipilimumab Improves Survival Versus Sunitinib in mRCC

September 11th 2017

The combination of nivolumab (Opdivo) and ipilimumab (Yervoy) was superior to sunitinib (Sutent) monotherapy as first-line treatment of advanced or metastatic renal cell carcinoma.

Ramucirumab Improves PFS in Platinum-Refractory Urothelial Carcinoma

September 11th 2017

Ramucirumab (Cyramza) plus docetaxel improved progression-free survival over docetaxel alone in patients with advanced or metastatic urothelial cancer who have progressed on platinum-based chemotherapy.

CABOSUN Update Affirms PFS Advantage With Cabozantinib Over Sunitinib in Advanced RCC

September 11th 2017

Patients with untreated advanced renal cell carcinoma lived significantly longer without disease progression when they received the multikinase inhibitor cabozantinib (Cabometyx) as initial therapy versus sunitinib (Sutent).

Combination Lenvatinib/Pembrolizumab Has Antitumor Activity in Metastatic Clear Cell RCC

September 11th 2017

Lenvatinib (Lenvima) combined with pembrolizumab (Keytruda) demonstrated promising antitumor activity in patients with metastatic clear cell renal cell carcinoma.

Atezolizumab Plus Bevacizumab Shows Encouraging Clinical Activity in mRCC

September 11th 2017

Atezolizumab with bevacizumab provided improved progression-free survival over sunitinib in patients with untreated metastatic renal cell carcinoma.

Pembrolizumab Shows Greater Long-Term Benefits Versus Chemo for Urothelial Carcinoma

September 10th 2017

Mature results from the phase III KEYNOTE-045 study presented at the 2017 ESMO Congress demonstrated that overall survival with pembrolizumab (Keytruda) continued to improve compared to chemotherapy in patients with recurrent, advanced urothelial carcinoma.

Dr. Choueiri on Impact of CABOSUN Results in Renal Cell Carcinoma

September 10th 2017

Toni K. Choueiri, MD, clinical director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, discusses the significance of the phase II CABOSUN trial, which explored cabozantinib (Cabometyx) as a frontline therapy for patients with renal cell carcinoma (RCC).

Role of PD-L1 Testing in Kidney Cancer

September 8th 2017

Emerging Immunotherapy Combinations in Kidney Cancer

September 8th 2017

Frontline Clinical Trials in Renal Cell Carcinoma

September 8th 2017

RCC: Following Patients on Immunotherapy Vs TKI Therapy

September 8th 2017

Second-Line Decision-Making in Kidney Cancer

September 8th 2017